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http://dx.doi.org/10.1016/j.pedneo.2Background: The aim of this study was to identify high-risk newborns who will subsequently
develop significant hyperbilirubinemia Days 4 to 10 of life by using the clinical data from the
first three days of life.
Methods: We retrospectively collected exclusively breastfeeding healthy term and near-term
newborns born in our nursery between May 1, 2002, to June 30, 2005. Clinical data, including
serum bilirubin were collected and the significant predictors were identified. Bilirubin level
15mg/dL during Days 4 to 10 of life was defined as significant hyperbilirubinemia. A predic-
tion model to predict subsequent hyperbilirubinemia was established. This model was exter-
nally validated in another group of newborns who were enrolled by the same criteria to test
its discrimination capability.
Results: Totally, 1979 neonates were collected and 1208 cases were excluded by our exclusion
criteria. Finally, 771 newborns were enrolled and 182 (23.6%) cases developed significant hy-
perbilirubinemia during Days 4 to 10 of life. In the logistic regression analysis, gestational
age, maximal body weight loss percentage, and peak bilirubin level during the first 72 hours
of life were significantly associated with subsequent hyperbilirubinemia. A prediction model
was derived with the area under receiver operating characteristic (AUROC) curve of 0.788.of Pediatrics, National Taiwan University Hospital, 8 Chung-Shan South Road, Taipei 10002, Taiwan.
w (P.-N. Tsao).
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Significant neonatal hyperbilirubinemia 355Model validation in the separate study (N Z 209) showed similar discrimination capability
(AUROC Z 0.8340).
Conclusion: Gestational age, maximal body weight loss percentage, and peak serum bilirubin
level during the first 3 days of life have highest predictive value of subsequent significant hy-
perbilirubinemia. We provide a good model to predict the risk of subsequent significant hyper-
bilirubinemia.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Neonatal hyperbilirubinemia is the leading cause of read-
mission of newborns in their first week of life.1 After
implementation of the breastfeeding promotion in
maternal facilities program to promote exclusive breast
feeding in Taiwan, the incidence of neonatal hyper-
bilirubinemia increased significantly.2 Severe neonatal
hyperbilirubinemia can occur without apparent reason in
healthy breastfed term infants and some develop ker-
nicterus. The American Academy of Pediatrics (AAP) clin-
ical practice guideline recommends that all newborn
infants should be assessed before discharge for the risk of
developing significant neonatal hyperbilirubinemia.3 The
peak serum bilirubin level usually occurs during Days 4 to 6
of life.2,4 Dalal et al5 found that single transcutaneous
bilirubin measurements at 30e48 hours can be used to
predict subsequent hyperbilirubinemia at 5 days old;
however, the case number is relatively small. The aim of
this study was to establish a predicting model by using
clinical data from the first 3 days of life for prediction of
subsequent hyperbilirubinemia in exclusively breastfed
term and late preterm neonates.2. Methods2.1. Study group
We retrospectively collected exclusively breastfeeding
healthy term and late preterm newborns born in our
nursery between May 1, 2002, and June 30, 2005. Infants
who weighed above 2500 g at birth with a gestational age of
at least 35 weeks were eligible for the study. Those
neonates who had evidence of hemolysis, Glucose-6-
phosphate dehydrogenase deficiency, cephalohematoma,
congenital infection, perinatal asphyxia, or any major
organ anomalies were excluded. Neonates who developed
early hyperbilirubinemia within 72 hours of age were also
excluded. Serum bilirubin was checked routinely at 3 days
old or if icteric skin appearance was identified. All neonates
with serum bilirubin above 11 mg/dl were scheduled for
routine outpatient follow-up 2 days later.
Clinical data, including gestational age, sex, birth mode,
Apgar scores, feeding (formula or breast milk), birth body
weight, daily body weight, maximal body weight loss, daily
stool passage times, daily urine output times, and total
serum bilirubin (TSB) were collected from review of themedical records. Hyperbilirubinemia during Days 4 to 10 of
life was defined as serum bilirubin level 15mg/dL.2.2. Statistical analysis
Exhaustive review of clinical risk factors and univariate
logistic regression analysis with stepwise variable selection
were performed to identify significant predictors among
the collected clinical data. Then multivariate logistic
regression was performed to establish predicting model for
subsequent hyperbilirubinemia. The area under receiver
operating characteristic (AUROC) curve was calculated for
the measurement of diagnostic discrimination.2.3. Model validation
This risk prediction model was externally validated in
another study of newborns who were born in our nursery
between January 1, 2009, and April 30, 2009. They were
enrolled by the same inclusion and exclusion criteria. Model
validation was performed in this study to test the discrim-
ination capability of our prediction model.3. Results
During the study period, a total of 1979 neonates were
born, of whom 310 neonates were excluded because they
met our exclusion criteria. In addition, a further 795 infants
were excluded from this study because they were not
exclusively breastfed. The remaining 874 infants were
further analyzed. Among them, 67 neonates who developed
significant hyperbilirubinemia within 72 hours of life and 36
infants lacked TSB data within 72 hours of life. Finally, 771
exclusively breastfeeding neonates were enrolled and 182
newborns (23.6%) developed subsequent significant hyper-
bilirubinemia during Days 4 to 10 of life (Figure 1).
In the univariate logistic regression analysis, gestational
age,maximal bodyweight loss percentage and bilirubin level
during first 72 hours of life were significantly associated with
subsequent hyperbilirubinemia (Table 1). In themultivariate
logistic regression analysis, the multivariate-adjusted odds
ratio (95% confidence interval) of gestational age, maximal
body weight loss percentage, and peak bilirubin level during
the first 72 hours of life were 0.78 (0.66e0.91), 1.22
(1.11e1.35), and 1.58 (1.44e1.74), respectively (Table 2).
Therefore, the estimated probability of developing subse-
quent significant hyperbilirubinemia (i.e., the predicted
Figure 1 The enrolment and follow-up of two separate study subjects. Model derivation was developed from Study 1 and model
validation was performed in Study 2.
356 H.-C. Huang et alvalue, denoted as bP), could be calculated using the following
equation:
bPZ
eð2:1016  0:2510  GA þ 0:1993  maxloss% þ 0:4584  peakbilÞ
1þ eð2:1016  0:2510  GA þ 0:1993  maxloss% þ 0:4584  peakbilÞ;
where GA is gestational age in weeks, maxloss% is the
maximal body weight loss within 72 hours of life in
percentage, and peakbil is the peak TSB level within 72Table 1 Gestational age, maximal body weight loss
percentage, and serum bilirubin level were strongly asso-
ciated with subsequent significant hyperbilirubinemia in
univariate logistic regression analysis.
Crude OR (95% CI) p value
Sex of baby 1.16 (0.84e1.60) 0.3599
GA 0.74 (0.64e0.85) <0.0001
BBW, per 100gm 1.01 (0.97e1.06) 0.5989
Max BW loss (%) 1.16 (1.07e1.26) 0.0004
Bil24h 1.48 (1.26e1.73) <0.0001
Bil48h 1.74 (1.51e2.00) <0.0001
Bil72h 1.85 (1.61e2.11) <0.0001
Peak bilirubin before 72 hrs 1.57 (1.44e1.72) <0.0001
Bil24h Z serum bilirubin level at 24 hours of age; BBW Z birth
body weight; CI Z confidence interval; GA Z gestational age;
Max BW loss Z maximal body weight loss; OR Z odds ratio.hours of life. The AUROC curve showed that this prediction
model incorporating gestational, maximal body weight loss
percentage, and peak bilirubin level during the first 72
hours of life has better diagnostic discrimination
(AUROC Z 0.788) as compared with using bilirubin level
before discharge only (AUROCZ 0.766; Figure 2A). By using
the predicted probability of 0.177 as the cut-off point, the
sensitivity was 90% and specificity was 66.0%.Table 2 In multivariate logistic regression, 3 significant
predictors were used to establish the prediction model. The
estimated probability (bP) can be calculated by the func-
tional equation.
Regression
coefficient
OR (95% CI) p value
Intercept 2.1016 0.5182
GA 0.2510 0.78 (0.66e0.91) 0.0023
Max BW loss (%) 0.1993 1.22 (1.11e1.35) <0.0001
Peak Bil
before 72 h
0.4584 1.58 (1.44e1.74) <0.0001
Prediction equation:
bPZ
eð2:1016  0:2510  GA þ 0:1993  maxloss% þ 0:4584  peakbilÞ
1þ eð2:1016  0:2510  GA þ 0:1993  maxloss% þ 0:4584  peakbilÞ
CI Z confidence interval; GA Z gestational age; Max BW
loss Z maximal body weight loss; OR Z odds ratio.
Figure 2 (A) Receiver operating characteristic (ROC) curve for the prediction model in study 1. The area under the ROC (AUROC)
curve was 0.788; (B) model validation applying the derived model-to-model validation set showed similar discrimination capability
with the AUROC Z 0.834.
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tively collected 760 exclusively breastfeeding healthy term
and near-term newborns who were born in our nursery by
the same criteria. A total of 144 neonates were excluded by
our exclusion criteria and 333 further infants were excluded
because they were not exclusively breast fed, leaving
a total of 283 infants. Among them, 73 neonates who
developed significant hyperbilirubinemia within 72 hours of
life received phototherapy or blood exchange therapy
before discharge. One baby lacked TSB data within 72 hours
of life. Finally, 209 exclusive breastfeeding newborns were
enrolled and 50 newborns (23.9%) developed subsequent
significant hyperbilirubinemia during Days 4 to 10 of life
(Figure 1). Applying the derived model to this separate
population (N Z 209) showed similar good discrimination
capability (AUROC Z 0.8340; Figure 2B).4. Discussion
Bilirubin level obtained before discharge can be plotted on
an hour-specific bilirubin nomogram to calculate an infant’s
bilirubin percentile with respect to age in hours.6,7
Although the predischarge bilirubin “risk zone” has been
shown to be a good predictor of subsequent risk of hyper-
bilirubinemia,7e10 clinical risk factors are known to modify
the course of neonatal hyperbilirubinemia. Some studies
have identified that some clinical risk factors significantly
improve prediction of subsequent hyperbilirubinemia
compared with serum bilirubin levels alone.8,9,11,12 Some
studies used clinical risk factors associated with bilirubin
screen as risk indexes for predicting hyperbilirubinemia in
infants. However, risk indexes of most studies were not
validated in a group of infants separated from the group in
which it derived, which may cause overestimation of its
discrimination.13 Here, we provide a prediction model:
a prediction equation in which the estimation of the risk of
subsequent neonatal hyperbilirubinemia in each individual
infant could be possible and we showed its good discrimi-
native capability.
Gestational age was identified as a strong predictor of
significant hyperbilirubinemia. Other clinical factors did notincrease the predictive accuracy, which was compatible
with a previous study.14 Some reported risk factors, such as
blood type, positive direct Coombs test, or sibling history of
phototherapy were not taken into analysis because they
were not routinely checked in general practice.12 It was our
aim to establish a friendly practical prediction model, so
only common clinical parameters were used. Maximal body
weight loss percentage was identified as a good new
predictor in our study as well as previous reports.15,16
Inadequate calorie intake and dehydration were known to
be strongly associated with neonatal hyperbilirubinemia.
Maximal body weight loss percentage could reflect the
effect of inadequate feeding and dehydration.
In the univariate logistic regression, we found that TSB
at Days 1 (24 hours), 2 (48 hours), and 3 (72 hours) of life or
peak value were all significantly associated with subse-
quent significant hyperbilirubinemia (all with p value
< 0.0001). All TSB levels, checked at any time within the
first 3 days of life, were strongly associated with hyper-
bilirubinemia. This result further confirmed previous
studies to the effect that TSB level was the strongest
predictor for subsequent hyperbilirubinemia.7,17 Because
first- and second day bilirubin levels were only checked
when icteric appearance was noted by clinical judgments,
the predicting model was derived according to Day 3 TSB
value or peak TSB value. In multivariate logistic regression
and the calculated AUROC, model with peak TBS level
showed the best predictive accuracy. Although the peak
TSB usually occurred on the third day, the earlier elevated
TSB has some interference on subsequent significant
hyperbilirubinemia. Since this is a retrospective study, one
limitation is that the peak bilirubin level may have been
influenced by the timing of blood sampling. If we measure
the bilirubin levels at a specific time point, then we can
obtain the real peak bilirubin level for each case, which
may improve the accuracy of our prediction model.
However, for clinical practice, measuring the bilirubin level
at a specific time point for individual cases is not practi-
cable in most hospitals. Therefore, to use the peak bilirubin
levels before 72 hours may be an appropriate alternative to
predict subsequent hyperbilirubinemia that has been vali-
dated in two different data sets.
358 H.-C. Huang et alIn the era of universal bilirubin screen, the incidence of
severe hyperbilirubinemia has decreased but there was an
increase in the use of phototherapy.18,19 This is, at least in
part, due to an early discharge strategy. By risk calculation
and stratification, individualized follow-up programs and
management plans are possible. In our predicting model, by
using the predicted probability of 0.177 as the cut-off point,
the sensitivitywas90%and specificitywas66.0%. Byusing this
prediction model, we expect that we can identify the high-
risk infants in order to arrange more frequent outpatient
department (OPD) follow-up and family education to prevent
subsequent hyperbilirubinemia. However, further study is
required to prove this.
5. Conclusion
Gestational age, maximal body weight loss percentage, and
peak TSB level during the first 3 days of life have the
highest predictive value of subsequent significant hyper-
bilirubinemia. We provide a prediction model to calculate
the risk of each newborn, and the external validation
proves the discrimination capability of this tool. Therefore,
we hope that the individualized follow-up plan and
management can be achieved by using this prediction
model so as to decrease the incidence of subsequent
hyperbilirubinemia that requires phototherapy.
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